Driving research forward during the coronavirus pandemic
A survey of people with Parkinson’s, their carers and loved ones has shown that the majority are still comfortable taking part in research. 548 responses have shaped guidance aimed at researchers. It will help them adapt their studies to ensure the safety and comfort of people with Parkinson's during the coronavirus (COVID-19) pandemic.
Oxford researchers find molecule that may slow or stop the progress of Parkinson's
Parkinson's UK funded research suggests it may be possible to prevent the formation of protein clumps that cause problems in Parkinson's by using microscopic tweezers that pull apart the proteins. This could pave the way for a therapy that could slow or stop the progression of the condition.
$161M worth of Parkinson’s research funding awarded across the globe
The Aligning Sciences Across Parkinson’s (ASAP) initiative has announced the 21 teams to receive grant funding. The ambitious programme aims to accelerate the pace of discovery towards a cure for Parkinson’s.
Trial results show statin drug does not slow Parkinson's
Simvastatin is a drug already used to lower cholesterol, and prevent heart attacks and strokes. Initial results from a major clinical trial show it doesn't have potential to slow the progression of Parkinson's as previously hoped.
Precious brain tissue uncovers new insights about the causes of Parkinson’s
Tissue from the Parkinson’s UK Brain Bank has provided vital clues to why brain cells are lost in Parkinson's
New research uncovers structures of Parkinson’s-related protein
Scientists at the University Bath have improved our understanding of the potentially toxic structures that the protein, alpha-synuclein, can form.
Research shows bad dreams could predict future memory and thinking problems
Researchers in Portugal have discovered that the content of dreams, particularly those with negative emotions, may predict long-term cognitive decline in people with Parkinson’s.
Link found between diabetes and increased Parkinson’s risk
An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
Biogen step in to take forward promising gene-based drugs for Parkinson’s
Major pharmaceutical company Biogen is investing $1billion to take LRRK2 inhibitors into large scale clinical trials in 2021.